NCT05656144

Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma

A Single-arm, Single-center, Open-label, Phase II Study Assessing Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 49 (estimated)
• Sponsor: Peking University Cancer Hospital & Institute · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study was to evaluate the efficacy and safety of Cadonilimab monotherapy in the treatment of patients with advanced soft tissue sarcoma who have received at least one chemotherapy (including anthracyclines) for advanced diseases (excluding alveolar soft part sarcoma).

Detailed description

After being informed about the study and potential risks, all patients giving written informed consent will undergo a screening period (≤28 days) to determine eligibility for study entry. At week 0, patients who meet the eligibility requirements will be treated with Cadonilimab monotherapy.

Conditions

• Soft Tissue Sarcoma

Interventions

Type	Name	Description
DEVICE	Cadonilimab	AK104, 6mg/kg, Q2W

Timeline

• Start date: 2023-02-01
• Primary completion: 2024-12-01
• Completion: 2025-06-01
• First posted: 2022-12-19
• Last updated: 2022-12-19